About Advanced glycosylation end product-specific receptor
Advanced glycosylation end product-specific receptor (AGER) is a protein
from Homo sapiens identified by UniProt accession
Q15109, 404 residues long.
MolForge cross-references it against 0 known binders and
578 disease associations.
Target properties
| Protein name | Advanced glycosylation end product-specific receptor |
| UniProt accession | Q15109 |
| Gene | AGER |
| Organism | Homo sapiens |
| Length | 404 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (578)
Diseases linked to this target (Open Targets).
- FEV/FVC ratio · score 0.45
- chronic obstructive pulmonary disease · score 0.36
- blood protein measurement · score 0.34
- pulmonary function measurement · score 0.31
- smoking behaviour measurement · score 0.25
- lymphocyte count · score 0.21
- Alzheimer disease · score 0.18
- sRAGE measurement · score 0.16
- medulloblastoma · score 0.14
- serum alanine aminotransferase measurement · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15109-F1 | alphafold | PREDICTED | 82.80 | — |
Amino-acid sequence (404 residues)
MAAGTAVGAW VLVLSLWGAV VGAQNITARI GEPLVLKCKG APKKPPQRLE WKLNTGRTEA WKVLSPQGGG PWDSVARVLP NGSLFLPAVG IQDEGIFRCQ AMNRNGKETK SNYRVRVYQI PGKPEIVDSA SELTAGVPNK VGTCVSEGSY PAGTLSWHLD GKPLVPNEKG VSVKEQTRRH PETGLFTLQS ELMVTPARGG DPRPTFSCSF SPGLPRHRAL RTAPIQPRVW EPVPLEEVQL VVEPEGGAVA PGGTVTLTCE VPAQPSPQIH WMKDGVPLPL PPSPVLILPE IGPQDQGTYS CVATHSSHGP QESRAVSISI IEPGEEGPTA GSVGGSGLGT LALALGILGG LGTAALLIGV ILWQRRQRRG EERKAPENQE EEEERAELNQ SEEPEAGESS TGGP
Explore Advanced glycosylation end product-specific receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets